Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Notes Payables (2016 - 2019)

Arrowhead Pharmaceuticals' Notes Payables history spans 8 years, with the latest figure at $2.7 million for Q3 2019.

  • For Q3 2019, Notes Payables rose 1106.33% year-over-year to $2.7 million; the TTM value through Sep 2019 reached $2.7 million, up 1106.33%, while the annual FY2019 figure was $2.7 million, 1106.33% up from the prior year.
  • Notes Payables reached $2.7 million in Q3 2019 per ARWR's latest filing, roughly flat from $2.7 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $2.7 million in Q1 2019 to a low of $144435.0 in Q2 2016.
  • Average Notes Payables over 4 years is $887358.9, with a median of $214130.0 recorded in 2017.
  • Peak YoY movement for Notes Payables: rose 7.31% in 2017, then skyrocketed 1149.84% in 2019.
  • A 4-year view of Notes Payables shows it stood at $197713.0 in 2016, then increased by 7.34% to $212233.0 in 2017, then surged by 983.71% to $2.3 million in 2018, then rose by 17.39% to $2.7 million in 2019.
  • Per Business Quant, the three most recent readings for ARWR's Notes Payables are $2.7 million (Q3 2019), $2.7 million (Q2 2019), and $2.7 million (Q1 2019).